Intervention-related Deaths in the European Randomized Study of Screening for Prostate Cancer

Schroder, 2009, Screening and prostate-cancer mortality in a randomized European study, N Engl J Med, 360, 1320, 10.1056/NEJMoa0810084 Schroder, 2012, Prostate-cancer mortality at 11 years of follow-up, N Engl J Med, 366, 981, 10.1056/NEJMoa1113135 Schroder, 2014, Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up, Lancet, 384, 2027, 10.1016/S0140-6736(14)60525-0 Hugosson, 2019, A 16-yr follow-up of the European Randomized study of Screening for Prostate Cancer, Eur Urol, 76, 43, 10.1016/j.eururo.2019.02.009 De Koning, 2003, Determining the cause of death in randomized screening trial(s) for prostate cancer, BJU Int, 92, 71, 10.1111/j.1465-5101.2003.04402.x European Randomized Study of Prostate Cancer Screening. ERSPC webpage. http://www.erspc.org/. Makinen, 2008, Assessment of causes of death in a prostate cancer screening trial, Int J Cancer, 122, 413, 10.1002/ijc.23126 Kilpelainen, 2016, Estimating bias in causes of death ascertainment in the Finnish Randomized Study of Screening for Prostate Cancer, Cancer Epidemiol, 45, 1, 10.1016/j.canep.2016.08.022 Otto, 2010, Blinded and uniform causes of death verification in cancer screening: a major influence on the outcome of a prostate cancer screening trial?, Eur J Cancer, 46, 3061, 10.1016/j.ejca.2010.09.026 Godtman, 2011, High accuracy of Swedish death certificates in men participating in screening for prostate cancer: a comparative study of official death certificates with a cause of death committee using a standardized algorithm, Scand J Urol Nephrol, 45, 226, 10.3109/00365599.2011.559950 Wilson, 1927, Probable inference, the law of succession, and statistical inference, J Am Stat Assoc, 22, 209, 10.1080/01621459.1927.10502953 Brown, 2001, Interval estimation for a binomial proportion, Stat Sci, 16, 101, 10.1214/ss/1009213286 O’Farrell, 2015, Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer, J Clin Oncol, 33, 1243, 10.1200/JCO.2014.59.1792 Carlsson, 2019, Could differences in treatment between trial arms explain the reduction in prostate cancer mortality in the European Randomized Study of Screening for Prostate Cancer?, Eur Urol, 75, 1015, 10.1016/j.eururo.2019.03.010 Black, 2002, All-cause mortality in randomized trials of cancer screening, J Natl Cancer Inst, 94, 167, 10.1093/jnci/94.3.167 Penston, 2011, Should we use total mortality rather than cancer specific mortality to judge cancer screening programmes?, Yes. BMJ, 343, d6395, 10.1136/bmj.d6395 Yaffe, 2020, The value of all-cause mortality as a metric for assessing breast cancer screening, J Natl Cancer Inst, 112, 989, 10.1093/jnci/djaa025 Zappa, 2014, A different method of evaluation of the ERSPC trial confirms that prostate-specific antigen testing has a significant impact on prostate cancer mortality, Eur Urol, 66, 401, 10.1016/j.eururo.2013.12.055 van Leeuwen, 2013, Impacts of a population-based prostate cancer screening programme on excess total mortality rates in men with prostate cancer: a randomized controlled trial, J Med Screen, 20, 33, 10.1177/0969141313476632 Walter, 2017, Impact of cause of death adjudication on the results of the European prostate cancer screening trial, Br J Cancer, 116, 141, 10.1038/bjc.2016.378 Miller, 2015, Changes in and impact of the death review process in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial, Rev Recent Clin Trials, 10, 206, 10.2174/1574887110666150730120752 Turner, 2016, Contemporary accuracy of death certificates for coding prostate cancer as a cause of death: Is reliance on death certification good enough? A comparison with blinded review by an independent cause of death evaluation committee, Br J Cancer, 115, 90, 10.1038/bjc.2016.162 Carlsson, 2011, No excess mortality after prostate biopsy: results from the European Randomized Study of Screening for Prostate Cancer, BJU Int, 107, 1912, 10.1111/j.1464-410X.2010.09712.x Pinsky, 2014, Mortality and complications after prostate biopsy in the Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) trial, BJU Int, 113, 254, 10.1111/bju.12368